Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05421663




Registration number
NCT05421663
Ethics application status
Date submitted
10/06/2022
Date registered
16/06/2022
Date last updated
23/05/2024

Titles & IDs
Public title
A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Scientific title
A Phase Ib Multicenter, Open-Label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Secondary ID [1] 0 0
90014496LYM1001
Secondary ID [2] 0 0
90014496LYM1001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - JNJ-90014496

Experimental: JNJ-90014496 - Participants will receive intravenous (IV) infusion of autologous JNJ-90014496 on Day 1.


Other interventions: JNJ-90014496
JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)19 and CD20.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Occurrence of Adverse Events (AEs) [Safety and Tolerability]
Timepoint [1] 0 0
Up to 24 months
Primary outcome [2] 0 0
Determination of the Recommended Phase 2 Dose (RP2D) of JNJ-90014496 in Participants with Relapsed or Refractory B-cell non-Hodgkin lymphoma (B-NHL)
Timepoint [2] 0 0
Up to 24 months
Secondary outcome [1] 0 0
Overall Response (OR)
Timepoint [1] 0 0
Up to 24 months
Secondary outcome [2] 0 0
Time to Response (TTR)
Timepoint [2] 0 0
Up to 24 months
Secondary outcome [3] 0 0
Duration of Response (DOR)
Timepoint [3] 0 0
Up to 24 months
Secondary outcome [4] 0 0
Pharmacokinetic Evaluation of JNJ-90014496
Timepoint [4] 0 0
Up to 24 months

Eligibility
Key inclusion criteria
- Participant must be greater than or equal to (>=) 18 years of age, at the time of
signing informed consent

- Diagnosis of mature aggressive large B cell non-Hodgkin lymphoma or follicular
lymphoma

- Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20
positive

- Must have relapsed or refractory disease with the following indications for each
histologic subtype: Mature aggressive large B cell non-Hodgkin lymphoma (NHL) and
follicular lymphoma Grade 3b: Participants must have >= 2 lines of systemic therapy,
or >= 1 line of systemic therapy for participants who are ineligible for autologous
stem cell transplant; Follicular lymphoma Grade 1-3a and marginal zone lymphoma:
Participants must have >= 2 prior lines of anti-neoplastic systemic therapy.
Participants also must have prior exposure to an anti-CD20 monoclonal antibody

- Measurable disease as defined by Lugano 2014 classification

- Eastern cooperative oncology group (ECOG) performance status of either 0 or 1
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

- Diagnosis of Human herpes virus (HHV) 8-positive diffuse large B Cell lymphoma (DLBCL)

- Prior allogeneic hematopoietic stem cell transplantation (HSCT)

- Autologous stem cell transplant within 12 weeks of chimeric antigen receptor (CAR) T
cell infusion

- Uncontrolled active infections

- History of deep vein thrombosis or pulmonary embolism within six months of infusion
(except for line associated deep vein thrombosis [DVT])

- History of stroke, unstable angina, myocardial infarction, congestive heart failure
New York Heart Association (NYHA) Class III or IV, severe cardiomyopathy or
ventricular arrhythmia requiring medication or mechanical control within 6 months of
screening

- History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia,
cerebellar disease or neurodegenerative disorder

- Known history or prior diagnosis of optic neuritis or other immunologic or
inflammatory disease affecting the central nervous system

- Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic
gallstones)

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/08/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
28/10/2028
Actual
Sample size
Target
104
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
St. Vincent's Hospital Melbourne - Fitzroy
Recruitment hospital [2] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [3] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment postcode(s) [1] 0 0
3065 - Fitzroy
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment postcode(s) [3] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
New Jersey
Country [4] 0 0
United States of America
State/province [4] 0 0
Pennsylvania
Country [5] 0 0
United States of America
State/province [5] 0 0
Texas
Country [6] 0 0
United States of America
State/province [6] 0 0
Washington

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase Ib multicenter, open-label study of JNJ-90014496, an autologous bi-specific
chimeric antigen receptor (CAR) T-cell therapy, targeting both cluster of differentiation
(CD) CD19 and CD20 for the treatment of adult participants with relapsed or refractory B-Cell
non-Hodgkin lymphoma (r/r B-NHL).
Trial website
https://clinicaltrials.gov/ct2/show/NCT05421663
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
John Baird, M.D.
Address 0 0
City of Hope Medical Center
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Contact, M.D.
Address 0 0
Country 0 0
Phone 0 0
844-434-4210
Fax 0 0
Email 0 0
Participate-In-This-Study@its.jnj.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05421663